Skip to main content

Table 2 Clinical and laboratory adverse events

From: Natalizumab in the pediatric MS population: results of the Italian registry

Clinical adverse events Number of subjects
Headache 13
Upper respiratory disorders 9
Vertigo 7
Gastrointestinal disorders 5
Edema, itching, dermatitis 6
Herpes zoster 4
Restlessness 2
Urinary tract infections 3
Fatigue 4
Infections 2
Menstrual disorders 2
Ovarian cyst 1
Sacral cyst 1
Muscular pain 1
Weight loss 3
Depression 1
Hypertension 1
Tachycardia 1
Total 66
Laboratory abnormalities Number of subjects
Increased white blood cells 9
Increased bilirubin 2
Increased ALT/AST 2
Proteinuria 1
Anemia 1
Total 15